My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...